Phase I study of concurrent bevacizumab (Avastin) with involved-field thoracic radiotherapy for inoperable non-squamous non-small cell lung cancer, followed by both concurrent and maintenance bevacizumab

Trial Profile

Phase I study of concurrent bevacizumab (Avastin) with involved-field thoracic radiotherapy for inoperable non-squamous non-small cell lung cancer, followed by both concurrent and maintenance bevacizumab

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Apr 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov. Trial terminated due to toxicity.
    • 03 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top